Patents Assigned to Biosite Diagnostics
-
Patent number: 6156270Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.Type: GrantFiled: March 27, 1997Date of Patent: December 5, 2000Assignee: Biosite Diagnostics, Inc.Inventor: Kenneth Francis Buechler
-
Patent number: 6143576Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include, flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.Type: GrantFiled: March 3, 1997Date of Patent: November 7, 2000Assignee: Biosite Diagnostics, Inc.Inventor: Kenneth F. Buechler
-
Patent number: 6113855Abstract: Assay device structures for a device where fluid flows from a one region to another. The device structures have one or more capillarity-inducing structures; where the capillarity-inducing structure induces capillary force along an axis that is essentially perpendicular to the axis along which capillary force induced in another region of the device.Type: GrantFiled: November 15, 1996Date of Patent: September 5, 2000Assignee: Biosite Diagnostics, Inc.Inventor: Kenneth Francis Buechler
-
Patent number: 6106779Abstract: A lysis chamber of an assay device capable of producing lysis of cells in a sample fluid such as whole blood, said chamber comprising a surface which contacts the sample fluid when the sample fluid is placed into the assay device; and a lytic material immobilized on the surface, whereby cells of the sample fluid are lysed when they contact the lytic material. The chamber can delimit a capillary space, and lytic material can be saponin or a detergent. Methods employing devices comprising such chambers can assay for whole blood amounts of cyclosporin or hemoglobin A1c.Type: GrantFiled: October 2, 1997Date of Patent: August 22, 2000Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Jason Christopher Briggs, Scott Harold Rongey
-
Patent number: 6074616Abstract: A fluorometer for sensing the fluorescence of a sample utilizes an optical energy source for exciting a sample to be tested and an optical energy detector for detecting the emitted energy from the excited sample. Drive electronics are used for positioning the sample with respect to the optical components allowing a plurality of sample regions to be tested. A processor is utilized to control the operation of the test in accordance with test instructions and for processing the emitted energy detected from the sample to determine test results. A ROM chip socket accepts a plurality of ROM chips, wherein each ROM chip stores test data sets for one or more test types to be performed. ROM chips can be swapped to allow the fluorometer to be configured and reconfigured to perform a plurality of different tests. A communications interface facilitates the sharing of test information between the fluorometer and external entities.Type: GrantFiled: January 5, 1998Date of Patent: June 13, 2000Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Joseph M Anderberg, Paul H. McPherson
-
Patent number: 6057098Abstract: The invention is directed to inter alia two related but self-sufficient improvements in conventional display methods. The first improvement provides methods of enriching conventional display libraries for members displaying more than one copy of a polypeptide prior to affinity screening of such libraries with a target of interest. These methods can achieve diverse populations in which the vast majority of members retaining full-length coding sequences encode polypeptides having specific affinity for the target. In a second aspect, the invention provides methods of subcloning nucleic acids encoding displayed polypeptides of enriched libraries from a display vector to an expression vector without the need for clonal isolation of individual members. These methods result in polyclonal libraries of antibodies and other polypeptides for use, e.g., as diagnostic or therapeutic reagents.Type: GrantFiled: April 4, 1997Date of Patent: May 2, 2000Assignee: Biosite Diagnostics, Inc.Inventors: Joe Buechler, Gunars Valkirs, Jeff Gray
-
Patent number: 6037455Abstract: The present invention is directed to novel propoxyphene derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to propoxyphene and propoxyphene metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: November 9, 1992Date of Patent: March 14, 2000Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler
-
Patent number: 6019944Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include, flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.Type: GrantFiled: May 23, 1995Date of Patent: February 1, 2000Assignee: Biosite Diagnostics, Inc.Inventor: Kenneth F. Buechler
-
Patent number: 5985579Abstract: Methods and test devices for detecting the presence or amount of target ligand in non-competitive sandwich ligand-receptor assay processes. Antibodies which bind to the complex of ligand receptor and target ligand but do not bind significantly to the ligand receptor and which bind the target ligand with substantially less affinity than the complex are taught and their uses described. These assays can be used to eliminate the "hook" effect in non-competitive sandwich assays. Furthermore, the antibodies are selected and assay methods described so that, as a result of the assay process, no detectable response is observed due to the binding of antibody and ligand receptor in the absence of target ligand.Type: GrantFiled: June 2, 1995Date of Patent: November 16, 1999Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Gunars E. Valkirs
-
Patent number: 5965375Abstract: This invention provides methods, compositions, and kits for detecting the presence of toxigenic strains of C. difficile in a biological sample. One embodiment provides methods for C. difficile detection that involve assaying for both C. difficile glutamate dehydrogenase and C. difficile toxin A or toxin B. In another embodiment, the invention provides a highly sensitive assay for C. difficile toxin A that is useful for determining whether a C. difficile strain is toxigenic. This embodiment involves binding of toxin A to a moiety that reversibly binds to a capture moiety present on a magnetic bead. A magnetic field is applied to the sample to concentrate the toxin A, after which the magnetic beads are dissociated and removed from the solution to obtain a highly concentrated preparation of toxin A, thus making possible a very sensitive assay.Type: GrantFiled: April 4, 1997Date of Patent: October 12, 1999Assignee: Biosite DiagnosticsInventor: Gunars E. Valkirs
-
Patent number: 5947124Abstract: The present invention relates to methods for determining the time of a myocardial infarction in a patient by measuring the ratio of oxidized to reduced troponin I in a blood sample obtained from the patient. This ratio is measured through the use of two or more distinct components which specifically bind oxidized troponin I, reduced troponin I, and/or both forms of troponin I present in the blood sample. Each distinct component may be an antibody or an antibody fragment. The measured ratio reflects the time elapsed from the time of the myocardial infarction.Type: GrantFiled: March 21, 1997Date of Patent: September 7, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth Francis Buechler, Paul H. McPherson
-
Patent number: 5939272Abstract: Assay methods for performing non-competitive ligand-receptor assays, where said assays provide a sensible result when the target ligand identified by the assay is present at a concentration greater than a defined threshold concentration. The threshold concentration can be selected to be the upper limit of a normal range of values for a target ligand in a sample, so that an assay in accordance with the invention provides a sensible result only when the target ligand is present at elevated levels.Type: GrantFiled: June 11, 1997Date of Patent: August 17, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Gunars E. Valkirs, Richard R. Anderson
-
Patent number: 5922615Abstract: Devices for use in heterogeneous ligand-receptor assays, having a porous member in contact with a nonabsorbent textured surface, where the surface texturing is such that a capillary network is formed when in fluid communication with the porous member. More particularly, these devices comprise:(a) a porous member having (i) at least one binding agent capable of immobilizing at least one target ligand on the porous member from a fluid sample in at least one zone and (ii) a means for detecting the presence or amount of said target ligand as a result of the assay process; and(b) a nonabsorbent member in fluid communication with the porous member, the nonabsorbent member forming at least one capillary with the porous member so that when sample, alone or in combination with other fluids, is added to the porous member, fluid is drawn through the porous member.Type: GrantFiled: June 2, 1995Date of Patent: July 13, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Mark R. Nowakowski, Kenneth F. Buechler, Richard R. Anderson, Gunars E. Valkirs
-
Patent number: 5914241Abstract: An immunoassay is provided which is selective for an analyte over immunologically related substances which may be present in a sample to be tested. The presence of the analyte is detected using a first binding substance, typically an antibody, in the presence of a second binding substance, typically another antibody. The first binding substance recognizes an epitope which is characteristic of the analyte and cross-reacts with a related epitope on the cross-binding substance. The second binding substance preferentially binds the common epitope on the cross-binding substance, thus reducing non-specific binding of the first binding substance.Type: GrantFiled: January 19, 1993Date of Patent: June 22, 1999Assignee: Biosite Diagnostics, Inc.Inventor: Gunars E. Valkirs
-
Patent number: 5885527Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include, flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.Type: GrantFiled: May 23, 1995Date of Patent: March 23, 1999Assignee: Biosite Diagnostics, Inc.Inventor: Kenneth F. Buechler
-
Patent number: 5851776Abstract: Novel conjugates and competitive and non-competitive assays for simultaneously detecting the presence or amount of at least two target ligands capable of competing with a single conjugate for binding to at least two different ligand receptors. The invention teaches and claims binding domains coupled to a signal development element to form a conjugate where each binding domain comprises at least one ligand analogue or ligand receptor depending on assay design. The binding domains are constructed such that they function independently from one another in assays for their respective target ligands. Each binding domain may bind its respective binding partners in the assay without affecting the binding reactions of other binding domains coupled to the same signal development element.Type: GrantFiled: August 3, 1993Date of Patent: December 22, 1998Assignee: Biosite Diagnostics, Inc.Inventor: Gunars E. Valkirs
-
Patent number: 5824799Abstract: Water soluble hybrid phthalocyanine derivatives useful in competitive and noncompetitive assays immunoassays, nucleic acid and assays are disclosed and claimed having (1) at least one donor subunit with a desired excitation peak; and (2) at least one acceptor subunit with a desired emission peak, wherein said derivative(s) is/are capable of intramolecular energy transfer from said donor subunit to said acceptor subunit. Such derivatives also may contain an electron transfer subunit. Axial ligands may be covalently bound to the metals contained in the water soluble hybrid phthalocyanine derivatives. Ligands, ligand analogs, polypeptides, proteins and nucleic acids can be linked to the axial ligands of the dyes to form dye conjugates useful in immunoassays and nucleic acid assays.Type: GrantFiled: March 22, 1996Date of Patent: October 20, 1998Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Joseph B. Noar, Lema Tadesse
-
Patent number: 5795725Abstract: Assays and antibodies are disclosed for the detection and quantitation of cardiac specific troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I and T and the binary and ternary complexes may be related to the metabolic state of the heart. More specifically, immunoassays for determining the presence or amount of free, binary and ternary complexes of troponin I and T are claimed.Type: GrantFiled: April 18, 1995Date of Patent: August 18, 1998Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 5763189Abstract: Particles comprising an energy donor as a first component and a fluorescent dye as a second component positioned in said particles at an energy exchanging distance from one another, wherein the two components have a Stokes shift of greater than or equal to 50 nm, said particle having bound on its surface, a protein, polypeptide, nucleic acid, nucleotide or protein containing ligand analogue are disclosed and claimed. In addition, novel fluorescent dyes are described which exhibit intramolecular energy transfer for use to label various molecules, proteins, polypeptides, nucleotides and nucleic acids or to incorporate into particles.Type: GrantFiled: September 23, 1994Date of Patent: June 9, 1998Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, J. Barry Noar, Lema Tadesse
-
Patent number: 5710256Abstract: The present invention is directed to novel methadone derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to methadone and methadone metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: April 3, 1995Date of Patent: January 20, 1998Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler